PressDecember 28, 2021 Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial
PressDecember 27, 2021 Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder
PressDecember 22, 2021 Tryp Therapeutics Announces Fiscal Year 2021 Financial Results and Reports on Corporate Highlights
PressDecember 21, 2021 Optimi Health Receives Dealers License Inspection and Introduces Quality Assurance Department
PressDecember 20, 2021 HAVN Life Enters into Definitive Agreement to Acquire Spore Life Sciences Inc.
PressDecember 20, 2021 PharmaTher Enters Into Process Development Agreement With LTS LOHMANN for Ketamine Microneedle Patch
PressDecember 17, 2021 MYND Life Sciences Acquires Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias
PressDecember 16, 2021 Entheon Biomedical Announces EEG Patent Application & Provides Research Update
PressDecember 15, 2021 Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share Lock-up Agreements
PressDecember 14, 2021 Atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index
PressDecember 10, 2021 Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003
PressDecember 10, 2021 Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives
PressDecember 9, 2021 MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System
PressDecember 8, 2021 Algernon Pharmaceuticals Completes Manufacturing of DMT, Appoints UK Stroke Experts for Phase 2
PressDecember 7, 2021 Mycotopia and Ei.Ventures sign LOI to Explore Merger and Formation of PSLY.COM, a $360 Million Transaction, And Will Apply To List Shares On NASDAQ
PressDecember 6, 2021 Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs
PressDecember 2, 2021 Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Study in Fibromyalgia
